BioSpace News Archive

Longeveron Inc. announced that management presented at the Second Euro-Geroscience Conference, being held from March 24-25, 2022 virtually and in Toulouse, France, and at a pre-meeting task force.

BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31, 2021 and provide a corporate update conference call on Tuesday, March 29, 2022 at 4:30 PM ET.

Surrozen, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.

IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or “the Company”), today announces it has initiated the third and final cohort of its Phase 1 clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinson’s disease.

Regulus Therapeutics Inc. (Nasdaq: RGLS), today announced the initiation of studies evaluating a library of oligonucleotides designed to block miR-155 for the potential to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease) under a collaboration agreement with the laboratories of Oleg Butovsky, Ph.D., and Howard L. Weiner, M.D., at Brigham and Women’s Hospital (BWH).

Remix Therapeutics, a biotechnology company developing small molecule therapies designed to modulate RNA processing and address the underlying drivers of disease, announced that management will participate in one-on-one meetings with investors at the SVB Leerink Biopharma Private Company Connect being held virtually from March 29-31, 2022.

Blade Therapeutics, Inc. today announced that the company will present data for cudetaxestat in three posters at the American Thoracic Society (ATS) 2022 International Conference, May 13-18, 2022, The Moscone Center, in San Francisco.

Tanner Pharma Group, an international distributor of essential medicines, announced that it has significantly increased its inventory of Leukine (sargramostim, yeast-derived rhuGM-CSF) to be held in Europe.

Psilera, Inc. has named Daniel N. Santiago, Ph.D. as the Director and Head of their Computational Chemistry Department. Dr. Santiago’s appointment is vital to continuing the growth of Psilera’s machine learning and artificial intelligence drug discovery platform.

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), today announced that it has entered into a research and collaboration agreement with the University of the Witwatersrand, Johannesburg (Wits) represented by Wits Commercial Enterprise (Pty) Ltd, a wholly owned subsidiary of the University whose mandate is to protect and manage the University’s intellectual property.